Back HIV/AIDS HIV/AIDS Topics HIV Treatment

6. HIV Drugs: Few New Approvals, but Pipeline Looks Promising

HIV drug development news in 2014 included approval of a new single-tablet regimen and 2 more components of antiretroviral therapy (ART). Promising candidates in the pipeline include a better-tolerated version of tenofovir, a NNRTI with fewer neuropsychiatric side effects, and potential long-acting injectables that may be useful for treatment or pre-exposure prophylaxis.

alt

Read more:

8. HIV Treatment Cascade: Majority in U.S. Have Uncontrolled Virus

On the HIV treatment cascade front, the Centers for Disease Control and Prevention reported in December that less than one-third of people living with HIV in the U.S. have an undetectable viral load, with most of the drop-off attributable to people who had been diagnosed with HIV but did not go on to receive further care

alt

Read more:

HIV Drug Therapy: Lower-dose Efavirenz Equally Effective with Fewer Side Effects

A reduced dose of efavirenz (Sustiva or Stocrin) for first-line HIV therapy suppressed viral load as well as the standard dose, but was associated with fewer characteristic side effects, researchers reported at the recent HIV Drug Therapy 2014 meeting in Glasgow. A related study found that half the dose maintained viral suppression in people with high efavirenz levels in their blood.

alt

Read more:

CCR5-Delta-32 Stem Cell Transplants Unsuccessful in 6 Patients -- Berlin Patient Remains the Sole HIV Cure

Bone marrow transplants from donors with a naturally occurring mutation that protects immune cells from HIV failed to cure 6 additional HIV positive blood cancer patients, leaving "Berlin Patient" Timothy Ray Brown as the only person to show no signs of HIV infection several years after receiving this type of transplant, Brown's doctor Gero Hütter reported in the December 18 New England Journal of Medicine. Brown recently published his own story of being the only man known to be cured of HIV.alt

Read more:

Happy Holidays from HIVandHepatitis.com

alt

HIVandHepatitis.com 2014 Conference Coverage

Links to full listing of on-site conference coverage during 2014.

alt

Read more:

HIV Drug Therapy: Efavirenz Not Linked to Higher Suicide Risk in D:A:D Cohort

People taking antiretroviral therapy (ART) regimens containing the NNRTI efavirenz (Sustiva) were not more likely to die due to suicide or psychiatric illness than those taking other drugs in the large D:A:D cohort, researchers reported last month at the HIV Drug Therapy 2014 meeting in Glasgow.

alt

Read more: